Neurotrophic factors in Huntington's disease

被引:73
|
作者
Alberch, J [1 ]
Pérez-Navarro, E [1 ]
Canals, JM [1 ]
机构
[1] Univ Barcelona, IDIBAPS, Sch Med, Dept Cell Biol & Pathol, E-08036 Barcelona, Spain
来源
NGF AND RELATED MOLECULES IN HEALTH AND DISEASE | 2004年 / 146卷
关键词
Huntington's disease; basal ganglia; striatum; neurotrophins; CNTF; GDNF; excitotoxicity; neuroprotection;
D O I
10.1016/S0079-6123(03)46014-7
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Huntington's disease is a neurodegenerative disorder characterized by the selective loss of striatal neurons and, to a lesser extent, cortical neurons. The neurodegenerative process is caused by the mutation of huntingtin gene. Recent studies have established a link between mutant huntingtin, excitotoxicity and neurotrophic factors. Neurotrophic factors prevent cell death in degenerative processes but they can also enhance growth and function of neurons that are affected in Huntington's disease. The endogenous regulation of the expression of neurotrophic factors and their receptors in the striatum and its connections can be important to protect striatal cells and maintains basal ganglia connectivity. The administration of exogenous neurotrophic factors, in animal models of Huntington's disease, has been used to characterize the trophic requirements of striatal and cortical neurons. Neurotrophins, glial cell line-derived neurotrophic factor family members and ciliary neurotrophic factor have shown a potent neuroprotective effects on different neuronal populations of the striatum. Furthermore, they are also useful to maintain the integrity of the corticostriatal pathway. Thus, these neurotrophic factors may be suitable for the development of a neuroprotective therapy for neurodegenerative disorders of the basal ganglia.
引用
收藏
页码:195 / 229
页数:35
相关论文
共 50 条
  • [1] Neurotrophic factors in neurodegenerative disorders: Model of parkinson's disease
    Garcia de Yebenes, Justo
    Angeles Mena, Maria
    NEUROTOXICITY RESEARCH, 2000, 2 (2-3) : 115 - 137
  • [2] Neurotrophic factors in neurodegenerative disorders: Model of parkinson’s disease
    Justo Garcia de Yebenes
    Maria Angeles Mena
    Neurotoxicity Research, 2000, 2 : 115 - 137
  • [3] Role of Neurotrophic Factors in Parkinson's Disease
    Tome, Diogo
    Fonseca, Carla Pais
    Campos, Filipa Lopes
    Baltazar, Graca
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (05) : 809 - 838
  • [4] Astrocytes and Huntington's Disease
    Khakh, Baljit S.
    Sofroniew, Michael V.
    ACS CHEMICAL NEUROSCIENCE, 2014, 5 (07): : 494 - 496
  • [5] Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: A potential therapy for Huntington's disease
    Sadan, O.
    Shemesh, N.
    Barzilay, R.
    Dadon-Nahum, M.
    Blumenfeld-Katzir, T.
    Assaf, Y.
    Yeshurun, M.
    Djaldetti, R.
    Cohen, Y.
    Melamed, E.
    Offen, D.
    EXPERIMENTAL NEUROLOGY, 2012, 234 (02) : 417 - 427
  • [6] Neurotrophic Factors as a Protective Strategy in Parkinson's Disease
    Diogenes, Maria Jose
    Outeiro, Tiago Fleming
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2010, 9 (06) : 754 - 763
  • [7] Dopamine and Huntington's disease
    Schwab, Laetitia C.
    Garas, Shaady N.
    Drouin-Ouellet, Janelle
    Mason, Sarah L.
    Stott, Simon R.
    Barker, Roger A.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2015, 15 (04) : 445 - 458
  • [8] Huntington's disease-like 2: a clinical, pathological, and molecular comparison to Huntington's disease
    Margolis, RL
    Holmes, SE
    CLINICAL NEUROSCIENCE RESEARCH, 2003, 3 (03) : 187 - 196
  • [9] Role of brain-derived neurotrophic factor in Huntington's disease
    Zuccato, Chiara
    Cattaneo, Elena
    PROGRESS IN NEUROBIOLOGY, 2007, 81 (5-6) : 294 - 330
  • [10] Huntington's disease: New frontiers for molecular and cell therapy
    Melone, MAB
    Jori, FP
    Peluso, G
    CURRENT DRUG TARGETS, 2005, 6 (01) : 43 - 56